AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery ...

The following is a listing of all residential property transfers in Ocean County reported during the week of June 15. There were 216 transactions posted during this time. During this period, the ...

Arcturus Therapeutics sued AbbVie and Capstan Therapeutics for allegedly misusing its lipid nanoparticle (LNP) delivery technology after former staff joined Capstan. The case spotlights the high ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

(RTTNews) - AbbVie (ABBV) has completed its acquisition of Capstan Therapeutics, bringing the biotech company under its umbrella. Capstan's lead program, CPTX2309, is a Phase 1 tLNP-based therapy that ...

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...

NORTH CHICAGO - AbbVie (NYSE:ABBV), a $365 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Tuesday it has completed its acquisition of Capstan Therapeutics, ...

AbbVie will pay US$2.1 billion to acquire Capstan Therapeutics and its in vivo CAR T technology, which uses mRNA-loaded lipid nanoparticles (LNPs) to reprogramme immune cells. Capstan’s lead asset is ...

Capstan Therapeutics — a biotechnology company pioneered by Penn researchers — was acquired by AbbVie in $2.1 billion deal. Capstan, which specializes in CAR-T therapies for autoimmune disorders, ...